20. Diego Ardigò, MD, PhD, Head of Research and Development, Global Rare Diseases, Chiesi Group

20. Diego Ardigò, MD, PhD, Head of Research and Development, Global Rare Diseases, Chiesi Group

Diego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase. Diego is an MD with a specialization in Internal Medicine. He obtained a PhD at the University of Parma (Italy) in cardiovascular pathophysiology and a post-doctoral fellowship in cardiovascular genomics at Stanford University (California, US). Before joining the industry, he worked at the University of Parma (Italy) in the field of cardiovascular and metabolic genomics, and as free-lance consultant for various academic institutions. He joined Chiesi in 2010, where he acted as Clinical Lead in the registration of the first stem cell therapy in EU and led the cross-company team (with uniQure BV) treating the first patient with a commercial gene therapy in EU. He also built an internal unit for the technical assessment of new in-licensing opportunities and the R&D infrastructure for due diligences. Diego is serving as chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and board member of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He is the author of 50+ indexed papers and a frequent speaker at international medical and industrial congresses.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(265)

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Robert Plenge, EVP & Chief Research Officer, BMS: Reinventing Drug Discovery

Synopsis: The drug discovery industry faces a persistent challenge: 9 out of 10 drugs entering the clinic fail, underscoring the need for a better path from biological insight to transformative medi...

24 Syys 45min

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Nello Mainolfi, Founder, President & CEO, Kymera: Pioneering Targeted Protein Degradation

Synopsis: What does it take to turn a once-fringe scientific idea into a new approach to drug discovery—and build a biotech company around it for the long haul? In this episode of Biotech 2050, hos...

16 Syys 38min

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery

Synopsis: The guest on today's podcast is a representative of Braidwell LP, a registered investment adviser. Braidwell invests on behalf of its clients and either holds, or may in the future hold, p...

3 Elo 47min

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient l...

22 Heinä 34min

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
utelias-mieli
rss-hereilla
tiedekulma-podcast
rss-duodecim-lehti
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
hippokrateen-vastaanotolla
rss-bios-podcast
docemilia
rss-politiikasta-podcast
rss-tiedetta-vai-tarinaa
rss-ranskaa-raakana
rss-lihavuudesta-podcast
radio-antro
rss-radplus